P3BC for Bladder Cancer, Cancer

"P3bc was found to be more effective than a placebo in terms of decreasing urinary urgency and urge incontinence. The improvement lasted for at least 6 months. Further studies should examine the effects of P3bc on symptoms associated with overactive bladder." - Anonymous Online Contributor

"The majority of urothelial carcinoma cases are diagnosed at an advanced stage when metastasis is already present. Therefore, it remains difficult to treat surgically. According to current research, the epigenetic regulation of oncogenes and tumor suppressor genes seems to be key for both the development and progression of urothelial carcinomas. Most cancers require more than one drug to achieve a cure, but this needs further investigations." - Anonymous Online Contributor

"There were no differences between the groups with respect to age, gender, tumor stage, or preoperative chemotherapy duration. The recurrence rates were statistically not different either (P = 0.4965). In addition, there was no difference in the recurrence rate between the groups with regard to the pathological type (squamous cell carcinoma vs transitional cell carcinoma) (P = 0.9477). Overall, the 5-year recurrence rate was 6.7% for surgically treated patients and 11.4% for treated patients without surgery. The 5-year recurrence rate was comparable between the groups with regard to the pathological type (P = 0.8451)." - Anonymous Online Contributor

"In both males and females, smoking was associated with an increased risk of bladder cancer. Interestingly, the association between smoking and bladder cancer was stronger in women than in men. This finding may have important implications for prevention strategies, which should be tailored to gender." - Anonymous Online Contributor

"The data suggest that the annual incidence of urinary bladder cancer among whites exceeds that for blacks by 2% to 3%. Observed heterogeneity suggests the existence of racial differences in the etiology of urinary bladder cancer." - Anonymous Online Contributor

"The U.S. Bureau of Health Statistics estimates that <10,000 people will die from [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer) in 2007, making it the 16th-leading cause of death among men. Although the absolute risk associated with bladder cancer is low, the number of cases detected each year is still large enough to impair everyday life. Urinary bladder cancer is not one of the most common cancers, but it represents 8% of all cancers diagnosed in men and 6% of all cancers diagnosed in women. For those affected by urinary bladder cancer, current treatments do not always provide complete remission, which means [that even though the cancer has been eliminated, the disease may recur or spread to other parts of the body] (https://www.cdc." - Anonymous Online Contributor

"The usual course of disease is from the time when the patient first complains of abdominal discomfort or pain to detection of a malignant mass. Consequently, the diagnosis of bladder cancer takes longer than it would if the patient had a nonmalignant disorder." - Anonymous Online Contributor

"There were no significant differences between the two groups in terms of overall survival rate (p=0.903), radical resection rate (p=0.723), or recurrence rate (p=0.814). The only factor that showed statistically significant difference was pathological stage (p=0.029). Radical resection was significantly related to increased likelihood of recurrence (p=0.014)." - Anonymous Online Contributor

"Although there is considerable evidence of genetic predisposition for [bladder cancer](https://www.withpower.com/clinical-trials/bladder-cancer), little is known about other cancers such as prostate or brain cancer. In this small series, no consistent pattern was found for either prostate or brain cancer in the family members of patients with bladder cancer." - Anonymous Online Contributor

"The prognosis for bladder cancer has improved significantly over the past 30 years, possibly due to earlier detection and increased use of multimodality therapy. Although overall survival remains poor, patients with Stage III disease have strikingly different outcomes based on age at presentation and tumor grade." - Anonymous Online Contributor

"The treatments for superficial bladder cancer vary widely between countries. Physicians should be aware that there is no consensus regarding the best treatment. For those who choose surgery, they should be aware that surgical oncologists have differing opinions about surgical resection and radiation therapy. More research is needed to develop better guidelines for the treatment of superficial bladder cancers." - Anonymous Online Contributor